Compare Sanofi SA (SNY) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sanofi SA vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Sanofi SA trades at $43.12 (market cap $104.06B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $211.72 (market cap $39.88B). The key difference: Sanofi SA is far larger — about 2.6× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Sanofi SA pays a 5.61% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.
| SNY | TTWO | |
|---|---|---|
Market Cap | $104.06B | $39.88B |
Sector | Health | Media |
52-Week High | $52.34 | $262.29 |
52-Week Low | $41.33 | $189.69 |
Enterprise Value | $124.09B | $41.00B |
Dividend Yield | 5.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Take-Two Interactive trades at $213.29, down 0.65% amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a -4.79% net margin and -$4.48B net loss for 2025, though recent earnings beats and GTA 6's November launch anticipation provide catalysts. Cash flow improved to $457M net inflow in 2025 from prior deficits, while debt-to-asset ratio rose to 39.87%.
Outlook hinges on GTA 6's execution, with 79% analyst buy ratings and $302.60 price target suggesting 42% upside. Risks include high valuation multiples (P/S 5.91, EV/EBITDA 32.78) and reliance on single-title success. Near-term volatility may persist pending Q3 earnings and preorder trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock
Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.
Read more on TTWO →
